UNSPSC 51283215: Relomycin

This classification denotes a macrolide antibiotic with the molecular formula C46H79NO17, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier E70CPL81IY. The term RELOMYCIN is an International Non-Proprietary Name or INN. RELOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: CCC1C(C=C(C=CC(=O)C(CC(C(C(C(CC(=O)O1)O)C)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CCO)C)C)COC4C(C(C(C(O4)C)O)OC)OC.

UNSPSC 51283215 Relomycin is a Commodity code that classifies pharmaceutical products, though recent state and local opportunities tagged under this code show minimal alignment with the specific drug name—the opportunities posted reflect procurement of other pharmaceutical inventory including antibiotics, opioid-reversal agents, and drug deactivation systems rather than relomycin specifically. State and local health departments and county public health agencies use this code tier to procure pharmaceutical supplies through both direct award and piggyback cooperative purchasing arrangements. The work involves securing pharmaceutical inventory for emergency preparedness, public health initiatives, and community health support, typically through fixed-price contracts with quarterly or as-needed delivery schedules.

Recent activity shows solicitations from state health departments and county health jurisdictions in Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract to Chartwell Rx LLC through the MMCAP Infuse consortium in August 2026 for antibiotic pharmaceuticals under an Invitation for Bid process, with a 12-month initial term and renewal options. Seminole County, Florida released an Invitation for Bid in June 2026 (due July 26, 2026) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building and potential FEMA funding. Neither opportunity explicitly required set-asides or business enterprise participation. The code shows activity concentrated in the Southeast and Midwest, though the sparse recent-opportunities record and the mismatch between the code's nominal drug name and the actual pharmaceutical products being procured suggests limited transactional volume under this specific commodity designation.